Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:33 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging
NCT04130438 · Stanford University · PHASE2 · terminated · last registry update 2025-02-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low recruitment, insufficient funding” | – | Registry record, Stanford University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRB1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-12-23Phase 3 first posted: Ain Shams University, Balanced anesthesia + Lidocaine spray (NCT07299630)
- 2025-12-11Also stopped (terminated): Hopital Charles Nicolle, Ephedrine (6 mg boluses) + Norepinephrine (10 µg boluses) (NCT07259655)
- 2025-11-20Phase 3 first posted: University of British Columbia, Pharmacological Rate Control (NCT07238452)
- 2025-10-09Results posted on the registry: Abramson Cancer Center at Penn Medicine, Carvedilol (NCT04023110)
- 2025-09-16Also stopped (withdrawn): Alcon Research, a drug against ADRB1 (NCT06592521)
- 2025-07-23Also stopped (withdrawn): Walter Reed Army Medical Center, a drug against ADRB1 (NCT00412295)
- 2025-07-16Results posted on the registry: Laboratorios Sophia S.A de C.V., Nanodrop® + Systane Balance (NCT04111965)
- 2025-06-13Phase 3 first posted: Universitas Indonesia, Standard General Anesthesia Induction Using Propofol, Fentanyl and Midazolam (NCT07019805)
- 2025-03-20Phase 3 first posted: Jagiellonian University, noradrenaline infusion for management blood pressure + standard blood pressure management (NCT06885268)
- 2025-03-03Phase 3 first posted: Ain Shams University, ACE Inhibitors + β -Blockers (NCT06853951)
- 2025-01-29Results posted on the registry: Beaver-Visitec International, Inc., a drug against ADRB1 (NCT04176965)
- 2024-11-29Results posted on the registry: University of Pennsylvania, a drug against ADRB1 (NCT03646643)
- 2024-11-20Phase 3 first posted: Shanghai Changzheng Hospital, Carvedilol and alverine (NCT06696248)
- 2024-11-19Results posted on the registry: OnPoint Vision Inc, a drug against ADRB1 (NCT04984590)
- 2024-10-30Results posted on the registry: Alcon Research, a drug against ADRB1 (NCT05481125)
- 2024-07-24Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Βeta-Blockers discontinued (with tapering) (NCT06518694)
- 2024-06-24Phase 3 first posted: Shanghai Changzheng Hospital, Alverine + Carvedilol (NCT06470386)
- 2024-06-03Also stopped (terminated): Asociación para Evitar la Ceguera en México, a drug against ADRB1 (NCT00925886)
- 2024-05-30Also stopped (terminated): Asociación para Evitar la Ceguera en México, a drug against ADRB1 (NCT00802269)
- 2024-05-28Results posted on the registry: Bausch & Lomb Incorporated, a drug against ADRB1 (NCT04192630)
- 2024-05-01Phase 3 first posted: Universitas Indonesia, Dexmedetomidine + Fentanyl (NCT06394375)
- 2024-04-16Results posted on the registry: University at Buffalo, Carvedilol Controlled Release (CR) + lisinopril (NCT00430040)
- 2024-04-16Also stopped (terminated): University at Buffalo, Carvedilol Controlled Release (CR) + lisinopril (NCT00430040)
- 2024-04-09Results posted on the registry: Weill Medical College of Cornell University, Beta blockers (NCT04757584)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision